文献速递炎症性肠病消化内镜

基于症状和生物标志物的克罗恩病内镜活动预测模型的系统评价与外部验证

Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-24

该研究系统评价了基于症状和生物标志物预测克罗恩病(CD)内镜活动的无创模型,并在TAILORIX(346次回结肠镜检查,155例患者)和UAI(93次回结肠镜检查,82例患者)数据集中外部验证了7个模型。在TAILORIX中,模型AUROC范围为0.61至0.81,粪便钙卫蛋白(FC)为0.79,C反应蛋白(CRP)为0.72;仅2个模型阴性预测值≥90%,但仅能正确预测3.2%至11.3%患者的内镜愈合。回结肠镜检查仍是评估CD黏膜活动与愈合的主要手段。

要点

  • 7个无创模型在外部验证中AUROC最高0.81,与FC(0.79)和CRP(0.72)接近。
  • 仅2个模型阴性预测值≥90%,但仅能正确预测3.2%至11.3%患者的内镜愈合。
  • FC在100-250 μg/g范围可避免66.5%-72.6%的回结肠镜检查,但18.7%-19.8%患者被错误分类。

核心结论

  • 7个无创预测模型中仅2个阴性预测值≥90%,且仅能正确预测小部分患者的内镜愈合,回结肠镜仍是评估CD黏膜活动与愈合的主要手段。

研究设计与样本

  • 系统评价已发表的无创诊断模型,以内镜活动或愈合为参考标准,并在TAILORIX试验(346次回结肠镜检查,155例患者)和Utrecht活动指数(UAI)研究(93次回结肠镜检查,82例患者)中进行外部验证。

主要发现

  • 共筛选5303篇文章,纳入21项研究的27个模型,其中7个模型可外部验证。
  • 在TAILORIX数据集中,7个模型识别内镜活动的AUROC范围为0.61(95%CI 0.51-0.70)至0.81(95%CI 0.76-0.86),FC的AUROC为0.79(95%CI 0.74-0.85),CRP为0.72(95%CI 0.66-0.77)。
  • UAI数据集的验证AUROC值相似。
  • 在TAILORIX和/或UAI数据集中,7个模型中的4个以及FC和CRP检测的阳性预测值≥90%;仅2个模型(非FC或CRP)的阴性预测值≥90%,正确预测内镜愈合的比例为3.2%至11.3%。
  • 以Herranz-Bachiller模型为例,阴性预测值92.1%、阳性预测值91.9%,正确识别35.7%可避免回结肠镜的患者,但错误识别3.2%的患者。

关键数值与推荐

  • 内镜活动定义为CD内镜严重指数(CDEIS)评分≥3。
  • FC浓度≤100 μg/g和≥250 μg/g可正确避免66.5%(TAILORIX)和72.6%(UAI)的回结肠镜检查,但分别导致18.7%和19.8%的患者被错误预测。
  • 仅2个模型阴性预测值≥90%,正确预测内镜愈合的比例为3.2%至11.3%。

临床怎么用

  • 基于症状和生物标志物的无创模型在识别CD内镜活动方面准确性有限,尚不能替代回结肠镜检查。
  • FC和CRP可用于辅助评估,但单独使用不足以可靠排除内镜活动。
  • 回结肠镜检查仍是评估CD黏膜疾病活动与愈合的主要手段。

局限性

  • 仅7个模型可进行外部验证,样本来自两个研究队列。
  • 无创模型仅能正确预测小部分患者的内镜愈合。
  • FC范围预测导致部分患者被错误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic healing, an important target of treatment for Crohn's disease (CD), requires ileocolonoscopy, which is costly and burdensome. We investigated whether published noninvasive models (based on symptoms and biomarkers) to evaluate CD activity have sufficient accuracy to replace ileocolonoscopy. METHODS: We performed a systematic review of published noninvasive diagnostic models to evaluate CD activity that used endoscopic features of activity (endoscopic activity) or healing as the reference standard. We externally validated these models for the outcome endoscopic activity (CD endoscopic index of severity scores, ≥3) using data from the a randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease (TAILORIX) study (346 ileocolonoscopies in 155 patients) and the Utrecht Activity Index (UAI) study (93 ileocolonoscopies in 82 patients). We calculated the area under the receiver operating characteristic curves (AUROCs) for the models using data from these studies, and compared the performance of these models against measurements of fecal calprotectin (FC) and C-reactive protein (CRP). RESULTS: We screened 5303 articles and identified 27 models (from 21 studies) for our analysis. Seven models could be validated externally; in the TAILORIX data set, these models identified patients with endoscopic activity with AUROC values ranging from 0.61 (95% CI, 0.51-0.70) to 0.81 (95% CI, 0.76-0.86). In this data set, the AUROC value for FC concentration was 0.79 (95% CI, 0.74-0.85) and the AUROC value for CRP level was 0.72 (95% CI, 0.66-0.77). The AUROC values for the validation in the UAI data set were similar. In the TAILORIX and/or UAI data set, 4 of the 7 models, as well as the FC and CRP assays, were able to identify patients with endoscopic activity with positive predictive values of 90% or more. Two of the 7 models (but not the FC or CRP values) identified patients without endoscopic activity with a negative predictive value (NPV) of 90% or more, leading to correct prediction of endoscopic healing in 3.2% to 11.3% of all patients. For example, applying the Herranz-Bachiller model (1 of 7 models) at a NPV of 92.1% and a positive predictive value of 91.9% correctly identified 35.7% of all patients in whom ileocolonoscopy could be avoided for expected endoscopic activity or healing but incorrectly identified 3.2% of all patients. Most ileocolonoscopies (66.5% in TAILORIX and 72.6% in the UAI of all ileocolonoscopies) could be avoided correctly based on concentrations of FC of 100 μg/g or less and 250 μg/g or higher. However, using this range of FC concentrations to identify patients who do not require ileocolonoscopy caused 18.7% of all patients in the TAILORIX cohort and 19.8% of all patients in the UAI cohort to be predicted incorrectly to have endoscopic activity or healing. CONCLUSIONS: In a systematic review and external validation of noninvasive models to identify patients with endoscopic activity of CD, we found only 2 of 7 models evaluated to have NPVs of 90% or more, however, leading to correctly predicted EH in only a small proportion of patients. Ileocolonoscopy therefore remains the mainstay to evaluate CD mucosal disease activity and healing.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Brand EC, Elias SG, Minderhoud IM, et al. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31881273. doi:10.1016/j.cgh.2019.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。